Patil Vijayalaxmi S, Barate Shraddha
Pathology, Shri B. M. Patil Medical College, Hospital and Research Centre, Bijapur Lingayat District Education (Deemed to Be University), Vijayapura, IND.
Pathology, Lilawati Heart Care and Medical Hospital, Lunawada, IND.
Cureus. 2024 Aug 20;16(8):e67279. doi: 10.7759/cureus.67279. eCollection 2024 Aug.
Interaction between the stromal and tumor cells is of crucial importance in breast cancer progression and response to therapy. A literature search has shown that stromal CD10 expression signifies the biological aggressiveness of various epithelial malignancies. Stromal markers are now becoming apparent as novel markers in evaluating the prognosis of invasive breast cancer and have not been studied substantially to date.
To study the immunohistochemical expression of CD10 in stromal cells of breast carcinoma and to correlate the expression of CD10 with various clinicopathological prognostic factors such as the size of the tumor, histological grade, lymph node status, and estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2/neu protooncogene (HER2-neu) status.
In the present study, a hospital-based cross-sectional study was conducted on 50 mastectomy specimens diagnosed with invasive breast carcinoma. The specimens of patients who had received neoadjuvant therapy or chemotherapy were excluded. Size of the tumor, grade of tumor on histopathology, lymph node involvement, and IHC status of ER, PR, and HER2-neu were noted. IHC staining for the CD10 marker was performed, and expression of stromal CD10 was correlated with these clinical-pathological prognostic factors.
CD10 expression in stromal cells of breast carcinoma was seen in 40 (80%) cases, and it showed a statistically significant association with histological grade (χ = 17.262; p-value < 0.0001), ER negativity (χ = 3.668; p-value < 0.045), and PR negativity (χ = 3.926; p-value < 0.048).
A strong association of stromal CD10 expression with a well-established negative prognostic marker such as a higher tumor grade, ER-negative status, and PR-negative status was noted and thus, stromal CD10 expression can be used as an independent prognostic marker in breast carcinoma.
基质细胞与肿瘤细胞之间的相互作用在乳腺癌进展及对治疗的反应中至关重要。文献检索表明，基质CD10表达标志着各种上皮性恶性肿瘤的生物学侵袭性。基质标志物正逐渐成为评估浸润性乳腺癌预后的新型标志物，而迄今为止尚未对其进行充分研究。
研究CD10在乳腺癌基质细胞中的免疫组化表达，并将CD10表达与各种临床病理预后因素相关联，如肿瘤大小、组织学分级、淋巴结状态以及雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2/neu原癌基因（HER2-neu）状态。
在本研究中，对50例经诊断为浸润性乳腺癌的乳房切除术标本进行了一项基于医院的横断面研究。排除接受过新辅助治疗或化疗的患者标本。记录肿瘤大小、组织病理学肿瘤分级、淋巴结受累情况以及ER、PR和HER2-neu的免疫组化状态。对CD10标志物进行免疫组化染色，并将基质CD10的表达与这些临床病理预后因素相关联。
40例（80%）乳腺癌基质细胞中可见CD10表达，且其与组织学分级（χ = 17.262；p值<0.0001）、ER阴性（χ = 3.668；p值<0.045）和PR阴性（χ = 3.926；p值<0.048）存在统计学显著关联。
注意到基质CD10表达与公认的负面预后标志物如较高的肿瘤分级、ER阴性状态和PR阴性状态之间存在强关联，因此，基质CD10表达可作为乳腺癌的独立预后标志物。
